Revenue segments as reported by the company.

Life Sciences and Applied Markets Group

Diagnostics and Genomics Group

Agilent CrossLab Group

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Agilent Technologies

Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. The Diagnostics and Genomics segment consists of activity providing active pharmaceutical ingredients for oligo-based therapeutics, as well as solutions that include reagents, instruments, software and consumables. The Agilent CrossLab segment includes startup, operational, training and compliance support, software as a service, and asset management and consultative services. The company was founded in May 1999 and is headquartered in Santa Clara, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Agilent Technologies posts strong Q1 earnings, eyes PFAS testing and CRISPR expansion

Agilent Technologies delivered robust Q1 results, raised full-year guidance, and remains confident in its growth drivers. Despite challenges in the genomics market and uncertainties ahead, the company is strategically positioned to capitalize on opportunities and drive continued success.

Agilent reports strong Q2 earnings but revises down second-half forecast

Agilent Technologies delivered strong Q2 results but revised down second-half forecasts due to economic uncertainties. The company remains focused on driving margin expansion, cost efficiencies, and customer service excellence. Challenges from macroeconomic factors and market dynamics are being addressed with a strategic outlook for long-term growth.

Agilent Technologies faces China revenue challenges but eyes growth opportunities

Agilent Technologies faces revenue challenges in China but sees growth opportunities in companion diagnostics and liquid biopsy markets. The company remains confident in its ability to drive earnings growth despite recent setbacks.

Agilent reports mixed Q4 results, eyes steady recovery in 2024

Agilent Technologies reported mixed Q4 results with revenue decline but exceeded EPS guidance. While facing challenges in China and certain segments, the company anticipates slow but steady recovery for FY 2024. Agilent is focusing on cost-saving measures, pricing trends, and investments in growth areas like genomics and environmental solutions.

Agilent reports Q1 revenue decline, eyes global growth opportunities

Agilent Technologies' Q1 performance showed revenue decline but with strengths in certain segments like ACG and consumables. Challenges include revenue declines in DGG and LSAG impacting margins. Opportunities lie in global growth prospects and potential market surprises.

Agilent Technologies faces revenue decline but eyes growth opportunities ahead

Agilent Technologies navigated a challenging market in Q2 2024 with revenue declines across all end markets. The company remains focused on customer-centric strategies, cost optimization, and growth investments while addressing visibility challenges and exploring opportunities in high-growth segments.

Agilent reports Q3 earnings beat, eyes growth through acquisitions

Agilent Technologies delivered a solid performance in Q3 2024, exceeding earnings per share guidance and raising revenue and EPS midpoint guidance.
While facing revenue decline, the company's strategic investments and acquisitions signal a focus on growth and innovation.
Challenges include market dynamics and integration risks, but opportunities exist in leveraging digital initiatives and financial strength for future growth.

Agilent Technologies reports robust Q4 performance and outlines growth strategies

Agilent Technologies' Q4 2024 earnings call highlighted strong financial performance, strategic acquisitions, and a focus on margin expansion for sustainable growth.
Despite regional challenges and market uncertainties, the company remains optimistic about future prospects and is committed to driving EPS growth.
With a new market-focused approach and ongoing transformation initiatives, Agilent is well-positioned to capitalize on opportunities and navigate potential challenges in FY 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Fortive

Investors looking for stocks in the Electronics - Testing Equipment sector might want to consider either Fortive (FTV) or Agilent Technologies (A). But which of these two companies is the best option for those looking for undervalued stocks?

FTV vs. A: Which Stock Should Value Investors Buy Now?

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the release of a new automated parallel capillary electrophoresis system for protein analysis – the Agilent ProteoAnalyzer system – at the 23rd Annual PepTalk Conference, being held January 16-19 in San Diego. This new platform simplifies and improves the efficiency of analyzing complex protein mixtures, a process central to analytical workflows across the pharma, biotech, food analysis, and academia secto.

Agilent Announces New ProteoAnalyzer System

Bristol-Myers

Core Laboratories Inc

Comcast

Compass Minerals

Campbell Soup

Corteva Inc

Disney

Estee Lauder

Emerson Electric

Etsy

Gilead Sciences

Huntington Ingalls Industries

Harley-Davidson

Honeywell

International Flavors & Fragrances

Kenvue

McDonald's

Altria

NIKE

Otis Worldwide

PepsiCo

Pfizer

Polaris

Ross Stores

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating).

U.S. Wide-Moat Stocks On Sale - The January 2024 Heat Map

Agilent Technologies, Inc. (A) Presents at J.P. Morgan 42nd Annual Healthcare Conference Transcript

Apple

AbbVie

Accenture Plc

Automatic Data Processing

Amgen

Amazon

Air Products and Chemicals

Ares Capital

Alexandria Real Estate Equities

ASML Hld

AvalonBay Communities

Broadcom

Booz Allen Hamilton Hld

Brookfield Asset Management

Brookfield Renewable Partners

SPDR Bloomberg 1-3 Month T-Bill ETF

Brookfield Infrastructure

Blackrock Inc

Broadridge Financial

British American Tobacco

Blackstone Group

Carrier Global

CME Group

Canadian National Railway Company

I express frustration with the constant negativity surrounding the idea that beating the market is impossible for the average investor. I share my personal success in beating the market in 2023, with a time-weighted return of 28.02%. I emphasize the importance of buying high-quality companies at fair prices and holding them for the long term, while also highlighting the power of compounding dividends.

How I Beat The Market Again In 2023

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the company has again been included in the Dow Jones Sustainability World Index and the North America Index for its strong environmental, social, and governance (ESG) performance. “It's an honor to be named in the Dow Jones Sustainability Indices for a ninth consecutive year. I am particularly proud of our team's progress in reducing emissions throughout our value chain and providing innovative solutions t.

Agilent Named to Dow Jones Sustainability Indices for Ninth Consecutive Year

Agilent Technologies' Q4 revenue was $1.69 billion, reflecting a 9.7% YoY decline, but the company achieved a healthy operating margin of 27.8%. Most regions showed sequential growth except for China, which saw a 31% decline. Agilent anticipates a slow but steady recovery in fiscal year 2024 with cost-saving measures and expects revenue in the range of $6.71 to $6.81 billion.

Agilent Technologies Hit A Homerun

American Tower

Andersons

CubeSmart

Edison

Ensign Group

Essential Properties Realty Trust Inc

Four Corners Property Trust

Getty Realty

Innovative Industrial Properties

Invitation Homes

Lincoln Electric Hlds

McCormick

Nucor

Realty Income Corp

Quanta Services

Raymond James

Schwab US Dividend Equity ETF

SEI Investments

Stryker

TFI International

Toro

U.S. Bancorp

York Water

24 dividend increases are expected next week, including Nucor's 50th annual dividend increase. Consistently increasing dividend payouts leads to better performance for companies.

24 Upcoming Dividend Increases, Including A New Dividend King, To Finish 2023

Agilent (A) reported earnings 30 days ago. What's next for the stock?

Why Is Agilent (A) Up 12.8% Since Last Earnings Report?

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced it has moved the company's Cell Analysis Division into its Diagnostics and Genomics Group (DGG) as part of a strategy to further strengthen growth opportunities for both organizations. “We believe having the cell analysis team as part of DGG is a natural fit given the markets they serve and the clear linkages to our genomics and diagnostics customers,” said Mike McMullen, Agilent president and CEO. “This i.

Agilent Makes Strategic Updates to Organizational Structure

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that CEO Mike McMullen and CFO Bob McMahon will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, Jan. 9, 2024, at 9:45 a.m. Pacific Time. A live audio webcast and replay of the presentation will be available on the Agilent Investor Relations website. About Agilent Technologies Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laborato.

Agilent to Present at the 42nd Annual J.P. Morgan Healthcare Conference

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the company's manufacturing facility in Waldbronn, Germany, has been named a Global Lighthouse by the World Economic Forum (WEF) for innovations that boost productivity, output, and quality. The recognition showcases Agilent's Waldbronn facility as a model of smart manufacturing enabled by Fourth Industrial Revolution (4IR) technologies, such as artificial intelligence and machine learning, robotics, data.

Agilent Again Named “Global Lighthouse” by World Economic Forum for Manufacturing Innovations

Agilent (A) adds a water immersion and confocal spinning disk technology to BioTek Cytation C10, enhancing image quality and reducing harmful effects on live-cell samples.

Agilent (A) Enhances BioTek Cytation C10 With New Technology

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the Agilent Resolve Handheld Raman Spectrometer has been recognized for excellence as a tool for emergency responders following independent use and evaluation by both the UK's National CBRN Centre, and the US' Department of Homeland Security. In the United Kingdom, the Resolve instrument received the National CBRN (Chemical, Biological, Radiological and Nuclear) Centre Certificate of Merit for 2023. T.

Agilent Resolve Raman Receives Multiple Recognitions for HazMat and CBRN Excellence

News for Agilent Technologies Stock (A)